Longeveron (LGVN) Net Income towards Common Stockholders (QoQ) (2020 - 2026)
Longeveron (LGVN) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.86% |
| Mar 31, 2026 | -1.86% |
| Dec 31, 2025 | 24.61% |
| Sep 30, 2025 | -43.62% |
| Jun 30, 2025 | 22.60% |
| Mar 31, 2025 | -59.18% |
| Dec 31, 2024 | 10.66% |
| Sep 30, 2024 | 61.66% |
| Jun 30, 2024 | -176.17% |
| Mar 31, 2024 | 28.43% |
| Dec 31, 2023 | -2.10% |
| Sep 30, 2023 | -4.83% |
| Jun 30, 2023 | 86.82% |
| Mar 31, 2023 | -858.40% |
| Dec 31, 2022 | 15.01% |
| Sep 30, 2022 | -6.52% |
| Jun 30, 2022 | -20.19% |
| Mar 31, 2022 | -109.12% |
| Dec 31, 2021 | 296.04% |
| Sep 30, 2021 | -14.17% |